Treatment Of Hepatitis C Virus Genotype 3 Infection With Direct-acting Antiviral Agents

dc.creatorZanaga
dc.creatorL. P.; Miotto
dc.creatorN.; Mendes
dc.creatorL. C.; Stucchi
dc.creatorR. S. B.; Vigani
dc.creatorA. G.
dc.date2016
dc.date2017-11-13T11:35:26Z
dc.date2017-11-13T11:35:26Z
dc.date.accessioned2018-03-29T05:49:34Z
dc.date.available2018-03-29T05:49:34Z
dc.identifierBrazilian Journal Of Medical And Biological Research. Assoc Bras Divulg Cientifica, v. 49, p. , 2016.
dc.identifier0100-879X
dc.identifier1678-4510
dc.identifierWOS:000386127000004
dc.identifier10.1590/1414-431X20165504
dc.identifierhttp://www.scielo.br/scielo.php?pid=S0100-879X2016001100302&script=sci_arttext
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/326635
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1363641
dc.descriptionHepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of directacting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatocellular carcinoma and lower sustained virological response (SVR) rates. Currently there are 4 recommended drugs for the treatment of HCV genotype 3: pegylated interferon (PegIFN), sofosbuvir (SOF), daclatasvir (DCV) and ribavirin (RBV). Treatment with PegIFN, SOF and RBV for 12 weeks has an overall SVR rate of 83-100%, without significant differences among cirrhotic and non-cirrhotic patients. However, this therapeutic regimen has several contra-indications and can cause significant adverse events, which can reduce adherence and impair SVR rates. SOF plus RBV for 24 weeks is another treatment option, with SVR rates of 82-96% among patients without cirrhosis and 62-92% among those with cirrhosis. Finally, SOF plus DCV provides 94-97% SVR rates in non-cirrhotic patients, but 59-69% in those with cirrhosis. The addition of RBV to the regimen of SOF plus DCV increases the SVR rates in cirrhotic patients above 80%, and extending treatment to 24 weeks raises SVR to 90%. The ideal duration of therapy is still under investigation. For cirrhotic patients, the optimal duration, or even the best regimen, is still uncertain. Further studies are necessary to clarify the best regimen to treat HCV genotype 3 infection.
dc.description49
dc.description11
dc.languageEnglish
dc.publisherAssoc Bras Divulg Cientifica
dc.publisherSão Paulo
dc.relationBrazilian Journal of Medical and Biological Research
dc.rightsaberto
dc.sourceWOS
dc.subjectHepatitis C Treatment
dc.subjectGenotype 3
dc.subjectSofosbuvir
dc.subjectDaclatasvir
dc.subjectRibavirin
dc.titleTreatment Of Hepatitis C Virus Genotype 3 Infection With Direct-acting Antiviral Agents
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución